Webinar: Pediatric Sickle Cell Disease: A Pharmacological Update: Past, Present, and Future-Webinar: Pediatric Sickle Cell Disease: A Pharmacological Update: Past, Present, and Future

Video Transcription

Video Summary

This webinar provided a detailed overview of pediatric sickle cell disease, covering its history, genetics, pathophysiology, complications, and treatment options. Dr. Clark and Dr. Rennell explained that sickle cell disease is an autosomal recessive disorder caused by a beta-globin mutation that produces abnormal hemoglobin S, leading to rigid, sickled red blood cells, vaso-occlusion, hemolytic anemia, pain crises, and progressive end-organ damage.<br /><br />The presenters reviewed global and U.S. epidemiology, emphasized the importance of universal newborn screening, and highlighted why early diagnosis improves survival and family education. Major complications discussed included vaso-occlusive pain crises, stroke, infection, acute chest syndrome, and iron overload from chronic transfusions.<br /><br />Medication management focused on standard therapies such as penicillin prophylaxis, vaccines, folic acid, hydroxyurea, and iron chelators. Hydroxyurea was described as first-line disease-modifying therapy because it increases fetal hemoglobin and reduces pain crises, transfusions, and hospitalizations. Iron overload management centered on chelators such as deferoxamine, deferasirox, and deferiprone, with nursing considerations for dosing, monitoring, and adverse effects.<br /><br />Newer agents included L-glutamine (Endari), a twice-daily oral therapy that may reduce oxidative stress and pain crises, and crizanlizumab, an IV monoclonal antibody that reduces vaso-occlusive events. Voxelotor was discussed as an example of accelerated approval that was later withdrawn due to safety concerns and increased adverse outcomes.<br /><br />The webinar concluded with practical nursing teaching points: distinguish side effects from dangerous reactions, support adherence, prepare families for frequent lab monitoring, and provide reassurance and resources to help children and families live well with sickle cell disease.

Keywords

pediatric sickle cell disease

hemoglobin S

autosomal recessive disorder

vaso-occlusion

hemolytic anemia

newborn screening

hydroxyurea

iron overload

crizanlizumab

L-glutamine

penicillin prophylaxis

stroke prevention